Who is sponsoring NCT02711865?

NCT02711865 is sponsored by Hillel Yaffe Medical Center.

What condition does NCT02711865 study?

NCT02711865 studies Ovarian Cancer.

What drugs are being tested in NCT02711865?

Interventions: IGF1R antibody MK0646, Saline solution.

What is the status of NCT02711865?

NCT02711865 is currently UNKNOWN.

Last reviewed 2016-03-13 · How we verify

Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer

NCT02711865 UNKNOWN

The main goal of this study is to employ a novel proteomic approach to identify predictive tumor biomarkers that will increase the efficacy of insulin-like growth factor (IGF1R) targeted therapy in epithelial ovarian cancer. It is expected that these predictive biomarkers will be applied to increase the response rate in selected groups of patients.

Details

Lead sponsor	Hillel Yaffe Medical Center
Status	UNKNOWN
Enrolment	20
Start date	2016-05
Completion	2019-05

Conditions

Ovarian Cancer

Interventions

IGF1R antibody MK0646
Saline solution

Primary outcomes

Responsive to IGF1R therapy — One year
Mean tumor volume will be calculated and growth inhibition will be reported as the percentage decrease of tumor volume compared with the control.

Countries

Israel